MiMedx Group Inc (MDXG) - Total Assets
Based on the latest financial reports, MiMedx Group Inc (MDXG) holds total assets worth $318.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of MiMedx Group Inc for net asset value and shareholders' equity analysis.
MiMedx Group Inc - Total Assets Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's total assets have evolved over time, based on quarterly financial data.
MiMedx Group Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
MiMedx Group Inc's total assets of $318.99 Million consist of 72.7% current assets and 27.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.6% |
| Accounts Receivable | $55.83 Million | 21.2% |
| Inventory | $23.81 Million | 9.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.63 Million | 4.4% |
| Goodwill | $19.44 Million | 7.4% |
Asset Composition Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MDXG company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MiMedx Group Inc's current assets represent 72.7% of total assets in 2024, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 39.6% of total assets in 2024, down from 45.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 7219.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 21.2% of total assets.
MiMedx Group Inc Competitors by Total Assets
Key competitors of MiMedx Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
MiMedx Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.41 | 4.10 | 2.71 |
| Quick Ratio | 3.95 | 3.53 | 2.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $196.41 Million | $130.20 Million | $101.45 Million |
MiMedx Group Inc - Advanced Valuation Insights
This section examines the relationship between MiMedx Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.20 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | 10.4% |
| Total Assets | $263.92 Million |
| Market Capitalization | $545.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MiMedx Group Inc's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: MiMedx Group Inc's assets grew by 10.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MiMedx Group Inc (2006–2024)
The table below shows the annual total assets of MiMedx Group Inc from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $263.92 Million | +10.40% |
| 2023-12-31 | $239.05 Million | +39.44% |
| 2022-12-31 | $171.43 Million | -8.78% |
| 2021-12-31 | $187.93 Million | -6.98% |
| 2020-12-31 | $202.03 Million | +64.46% |
| 2019-12-31 | $122.84 Million | 0.00% |
| 2018-12-31 | $122.84 Million | +1.31% |
| 2017-12-31 | $121.25 Million | -37.26% |
| 2016-12-31 | $193.26 Million | +42.20% |
| 2015-12-31 | $135.91 Million | +24.40% |
| 2014-12-31 | $109.26 Million | +29.00% |
| 2013-12-31 | $84.69 Million | +140.73% |
| 2012-12-31 | $35.18 Million | +29.84% |
| 2011-12-31 | $27.10 Million | +268.54% |
| 2010-12-31 | $7.35 Million | -24.14% |
| 2009-12-31 | $9.69 Million | -36.15% |
| 2008-12-31 | $15.18 Million | +8249074.46% |
| 2007-12-31 | $184.00 | -98.67% |
| 2006-12-31 | $13.85K | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more